Navigation Links
Ajinomoto Althea Inc. Appoints J. David Enloe Jr. as President and Chief Executive Officer
Date:1/6/2014

SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Ajinomoto Althea Inc., a leading Contract Manufacturing Organization providing development and manufacturing services for biotechnology and pharmaceutical companies, announced today the appointment of J. David Enloe Jr. as President and CEO. Mr. Enloe will be responsible for developing strategies to support the company's continued growth.

(Logo: http://photos.prnewswire.com/prnh/20131104/LA10040LOGO)

"We are delighted to welcome David as the new leader of Ajinomoto Althea's management team," said Dr. Hiroshi Shiragami, Co-Chair of Ajinomoto Althea Inc. "His unique depth of experience in the biotechnology industry, leadership abilities, financial management, manufacturing and contractual negotiation skills will be instrumental in supporting further expansion of our business."  

Mr. Enloe brings over 20 years of executive management experience most of that in biotechnology, drug development, and GMP manufacturing management.  Most recently, he served as the Head of the Viral Therapeutics Business Unit at Lonza AG, which provides process development, scale-up and GMP manufacturing of viral-based biologics for clients in the US, Europe and Asia.  David was the founder and CEO of Vivante GMP Solutions, Inc., which he subsequently sold to Lonza AG in 2010. Prior to this, he was President and CEO of Introgen Therapeutics, Inc., which later became the basis for Vivante.

"I can't think of a better fit for Ajinomoto Althea.  David's leadership and experience combined with the Ajinomoto Althea team will enhance the company's position as the most trusted outsource manufacturer for those developing tomorrow's successful therapeutics," stated Dr. Magda Marquet, Co-Chair of Ajinomoto Althea Inc.

"I am thrilled to be joining Ajinomoto Althea Inc. at this exciting stage in its history.  Althea has been an outstanding organization for many years now, and with the recent acquisition by Ajinomoto, the company is positioned to expand and grow into an even more significant player in the biologics production and fill/finish markets. The timing of this opportunity for me was perfect and I can't wait to get started," said Mr. Enloe.

Mr. Enloe joined the team effective December 16, 2013.  Dr. Hiroshi Shiragami and Dr. Magda Marquet will continue to serve Ajinomoto Althea Inc. as Co-Chairs of the Board of Directors.

About Ajinomoto Althea  Inc.

Ajinomoto Althea, Inc. is a fully integrated, contract development and manufacturing organization located in San Diego, CA providing clinical and commercial product development services.  Ajinomoto Althea offers cGMP drug product filling in both vials and syringes, and production of microbial-derived recombinant proteins and plasmid DNA. In conjunction with these manufacturing operations, Ajinomoto Althea offers comprehensive development services including: upstream and downstream process development, analytical development, lyophilization cycle, complex formulation, product release and ICH-compliant stability testing. Ajinomoto Althea's formulation technology platform includes Crystalomics®, a proprietary technology that offers a formulation solution for large molecule products that must be delivered at high concentrations or as sustained release formulations. Ajinomoto Althea also has an innovative and proven recombinant protein expression technology called Corynex®. For more information visit us at WWW.ALTHEATECH.COM.


'/>"/>
SOURCE Ajinomoto Althea Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Shanghai Ajinomoto Amino Acid Co., Ltd. Expands Amino Acid Production Capacity
2. Ajinomoto Althea, Inc. Selected As A Finalist In 26TH Annual CONNECT Most Innovative New Product Awards
3. Ajinomoto Co., Inc. Completes Acquisition of Althea Technologies, Inc.
4. Ajinomoto Co., Inc. Agrees To Acquire Althea Technologies, Inc.
5. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
6. Concord Medical Announces Results of 2013 Annual General Meeting; Appoints New Board Members
7. ViaCyte Appoints Mark Foletta, former CFO of Amylin, to its Board of Directors
8. BioMed Realty Trust Appoints Dr. William R. Brody, President Of The Salk Institute, To Its Board Of Directors
9. Vermillion Appoints Marian E. Sacco as SVP of Sales and Marketing and Chief Commercial Officer
10. Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
11. Hologic Appoints Stephen P. MacMillan President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):